Frank Sciurba, M.D., FCCP

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Sanofi/Regeneron
    Topic:
    Dupilimab
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    AstraZeneca
    Topic:
    Tozorakimab
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    GlaxoSmithKline
    Topic:
    Mepolizumab
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Genentech
    Topic:
    Astegolimab
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Sanofi/Regeneron
    Topic:
    Dupilimab
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    AstraZeneca
    Topic:
    Tozorakimab
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Verona Pharma
    Topic:
    Ensifentrine
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Nuvaira
    Topic:
    Targeted lung denervation
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Gala Therapeutics
    Topic:
    Bronchial rheoplasty
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Pulmonx
    Topic:
    Zephyr valves
    Date added:
    02/25/2026
    Date updated:
    02/25/2026
Return to 2026 California Thoracic Society Annual Educational Conference & Chronic Obstructive Pulmonary Disease Symposium